A standardized protocol for autologous stromal vascular fraction therapy in refractory thin endometrium and a prospective single-arm clinical study.
Peng T., Yang S., Fu L., Liang L., Liu F., Chen Y.
Cohort Study with a reported sample of 35, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Cohort Study
- Journal
- Stem Cell Res Ther (2026)
- Country
- England
- Reported sample size
- 35
- Source database
- PubMed
- PMID
- 42260663
- DOI
- 10.1186/s13287-026-05085-3
Abstract (original English)
Thin endometria are still a big obstacle in fertility treatments and often lead to poor pregnancy outcomes. Stromal vascular fraction (SVF) therapy has shown promise in the improvement of endometrial thickness. However, its preparation and treatment protocols lack standardization, and its efficacy and safety in assisted reproductive technology (ART) need to be further investigated. Through the collaboration of plastic surgery, obstetrics and gynecology as well as Good Manufacturing Practice (GMP) laboratory teams, an efficient protocol was developed for the completion of liposuction, hysteroscopy, SVF preparation, quality control and intrauterine infusion on the same day of treatment. This single-center, prospective, self-controlled prospective cohort study was performed at Peking University Third Hospital. Eligible participants (aged 20-45) were patients who had an endometrial thickness of < 7 mm on the day of ovulation or endometrial transformation in hormone replacement cycles. The primary outcome was the proportion of patients whose endometrial thickness increased to 7 mm. All participants were followed up during the first three menstrual cycles after treatment via hospital follow-up visits and then by telephone for the next two years. All adverse events related to the operation were recorded. Outcomes, including menstrual volume, endometrial thickness, pregnancy rate and o
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.